Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722839 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
A Phase 1 study of Nonneoplastic Condition, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT00722839 is a Phase 1 study of Nonneoplastic Condition that has completed, run by City of Hope Medical Center. The registered enrollment target is 68 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00722839, a Phase 1 study of Nonneoplastic Condition, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in healthy participants.
Conditions Studied
Interventions
- BIOLOGICAL PADRE-CMV fusion peptide vaccine
- BIOLOGICAL tetanus-CMV fusion peptide vaccine
- DRUG agatolimod sodium
Study Locations (1)
California
- City of Hope Comprehensive Cancer Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722839
The ClinicalTrials.gov registry entry for NCT00722839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonneoplastic Condition appearing as the primary indexed condition, and to 3 interventions - of which PADRE-CMV fusion peptide vaccine is the first listed.
NCT00722839 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00722839 about?
NCT00722839 is a clinical study titled "Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants". RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in healthy participants.
What is the current status of trial NCT00722839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2006-12. Estimated completion is 2012-04.
What conditions does trial NCT00722839 study?
This clinical trial studies the following conditions: Nonneoplastic Condition.
What interventions are being tested in trial NCT00722839?
The interventions under investigation include: PADRE-CMV fusion peptide vaccine (BIOLOGICAL), tetanus-CMV fusion peptide vaccine (BIOLOGICAL), agatolimod sodium (DRUG).
Who is sponsoring clinical trial NCT00722839?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00722839 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.